Search results for "severity"

showing 10 items of 1287 documents

Incretin-Based Therapies Role in COVID-19 Era: Evolving Insights

2020

The current coronavirus disease 2019 (COVID-19) pandemic has led the scientific community to breach new frontiers in the understanding of human physiology and disease pathogenesis. It has been hypothesized that the human dipeptidyl peptidase 4 (DPP4) enzyme receptor may be a functional target for the spike proteins of severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2). Since DPP4-inhibitors are currently used for the treatment of patients with type-2 diabetes (T2DM), there is currently high interest in the possibility that these agents, or incretin-based therapies (IBTs) in general, may be of benefit against the new coronavirus infection. Diabetes is associated with increased COV…

Prognostic variableCoronavirus disease 2019 (COVID-19)Pneumonia ViralIncretin030209 endocrinology & metabolism030204 cardiovascular system & hematologymedicine.disease_causeBioinformaticsIncretinsSeverity of Illness IndexGlucagon-Like Peptide-1 ReceptorBetacoronavirus03 medical and health sciences0302 clinical medicineDiabetes mellitusPandemicSeverity of illnessHumansHypoglycemic AgentsMedicinePharmacology (medical)PandemicsDipeptidyl peptidase-4CoronavirusPharmacologyDipeptidyl-Peptidase IV InhibitorsSARS-CoV-2business.industryCOVID-19medicine.diseaseDiabetes Mellitus Type 2Inflammation MediatorsCoronavirus InfectionsCardiology and Cardiovascular Medicinebusinessdiabetes DPP4 GLP1 incretins Betacoronavirus COVID-19 Coronavirus Infections Diabetes Mellitus Type 2 Dipeptidyl-Peptidase IV Inhibitors Glucagon-Like Peptide-1 Receptor Humans Hypoglycemic Agents Incretins Inflammation Mediators Pandemics Pneumonia Viral SARS-CoV-2 Severity of Illness Index
researchProduct

Asthma exacerbations and socio-economic status in French adults with persistent asthma: A prospective cohort study.

2017

Adults disadvantaged by poor socio-economic status (SES) are more severely affected by asthma compared to those with better SES. We aimed to determine whether the frequency of asthma exacerbations (AEx), as well as aspects related to AEx management, differed based on SES in patients treated with daily treatments.This study, part of the prospective observational cohort ASTRO-LAB, included French adult patients with persistent asthma. Patients were considered as low SES if they benefited from publicly funded special health insurance and/or were perceived as low SES by their general practitioner. AEx was defined as at least one of the following: asthma-related oral corticosteroid course, medic…

Pulmonary and Respiratory MedicineAdultHypersensitivity ImmediateMalePediatricsmedicine.medical_specialtyAdolescentGeneral PracticeComorbiditySeverity of Illness IndexBody Mass Index03 medical and health sciencesYoung Adult0302 clinical medicineImmunology and AllergyMedicineHumans030212 general & internal medicineSocial determinants of healthAnti-Asthmatic AgentsProspective StudiesProspective cohort studySocioeconomic statusAsthmaAsthma exacerbationsMedical Assistancebusiness.industrysocial sciencesmedicine.diseaseAsthma030228 respiratory systemSocioeconomic FactorsPediatrics Perinatology and Child HealthCohortpopulation characteristicsObservational studyFemaleFrancebusinessEmergency Service HospitalCohort studyThe Journal of asthma : official journal of the Association for the Care of Asthma
researchProduct

Dexamethasone treatment for the acute respiratory distress syndrome: a multicentre, randomised controlled trial

2020

Background There is no proven specific pharmacological treatment for patients with the acute respiratory distress syndrome (ARDS). The efficacy of corticosteroids in ARDS remains controversial. We aimed to assess the effects of dexamethasone in ARDS, which might change pulmonary and systemic inflammation and result in a decrease in duration of mechanical ventilation and mortality. Methods We did a multicentre, randomised controlled trial in a network of 17 intensive care units (ICUs) in teaching hospitals across Spain in patients with established moderate-to-severe ARDS (defined by a ratio of partial pressure of arterial oxygen to the fraction of inspired oxygen of 200 mm Hg or less assesse…

Pulmonary and Respiratory MedicineAdultMaleARDSmedicine.medical_treatmentSeverity of Illness IndexDexamethasonelaw.invention03 medical and health sciences0302 clinical medicineRandomized controlled triallawFraction of inspired oxygenIntensive careSeverity of illnessmedicineData monitoring committeeHumans030212 general & internal medicineGlucocorticoidsDexamethasoneAgedMechanical ventilationRespiratory Distress Syndromebusiness.industryMiddle Agedmedicine.diseaseRespiration ArtificialIntensive Care UnitsTreatment Outcome030228 respiratory systemAnesthesiaAdministration IntravenousFemalebusinessmedicine.drug
researchProduct

Blood pressure responsiveness to obstructive events during sleep after chronic CPAP

2003

The aim of this study was to investigate whether chronic continuous positive airway pressure (CPAP) affects blood pressure (BP) responsiveness to obstructive events occurring on the first night of CPAP withdrawal in obstructive sleep apnoea (OSA) after chronic treatment. Thirteen male subjects with severe OSA underwent nocturnal polysomnography with beat­by­beat BP monitoring before treatment and after 4.9±3.4 months of home CPAP (mean daily use 5.1±1.7 h). Variations in oxyhaemoglobin saturation (Δ S a,O2), systolic (Δ P s), and diastolic (Δ P d) BP within nonrapid eye movement apnoeas and hypopnoeas were measured on a sample of pre­ and post­treatment events. In addition, a pretreatment s…

Pulmonary and Respiratory MedicineAdultMaleBlood pressure Continuous positive airway pressure Hypoxaemia Polysomnographymedicine.medical_treatmentPolysomnographyPositive pressureDiastoleBlood PressurePolysomnographyRisk AssessmentSensitivity and SpecificitySeverity of Illness IndexSampling StudiesPositive-Pressure RespirationmedicineHumansContinuous positive airway pressureProspective StudiesMonitoring PhysiologicProbabilitySleep disorderSleep Apnea Obstructivemedicine.diagnostic_testbusiness.industryRespiratory diseaseApneaBlood Pressure DeterminationMiddle Agedmedicine.diseasePrognosisrespiratory tract diseasesBlood pressureTreatment OutcomeAnesthesiaLinear Modelsmedicine.symptombusiness
researchProduct

Outcome after mitral valve operations with depressed left ventricular function.

2012

We retrospectively investigated 42 patients (27 men, 15 women; mean age, 67 years) with severe mitral valve incompetence and endstage cardiomyopathy (ejection fraction <30%) who were operated on between January 2002 and March 2009. Of these, 14 were in New York Heart Association class IV, and 27 were in class III. The etiology was ischemic in 18 patients and idiopathic dilated in 24. Mitral valve repair was performed in 25 patients, and 17 had mitral valve replacement. The mean logistic EuroSCORE was 33.41. The mean follow-up was 44.52 months. There were no perioperative deaths. Three patients died within 30 days postoperatively. Thirty-day mortality was lower than predicted by EuroSCOR…

Pulmonary and Respiratory MedicineAdultMaleReoperationmedicine.medical_specialtyTime Factorsmedicine.medical_treatmentCardiomyopathyKaplan-Meier EstimateRisk AssessmentSeverity of Illness IndexVentricular Function LeftVentricular Dysfunction LeftRisk FactorsInternal medicineMitral valveGermanymedicineHumansCardiac Surgical ProceduresSurvival rateAgedProportional Hazards ModelsRetrospective StudiesAged 80 and overHeart Valve Prosthesis ImplantationMitral valve repairEjection fractionbusiness.industryMitral valve replacementMitral Valve InsufficiencyEuroSCOREStroke VolumeGeneral MedicinePerioperativeMiddle Agedmedicine.diseaseSurgerymedicine.anatomical_structureLogistic ModelsTreatment OutcomeMultivariate AnalysisCardiologyMitral ValveSurgeryFemaleCardiology and Cardiovascular MedicinebusinessCardiomyopathiesAsian cardiovascularthoracic annals
researchProduct

Prediction of bleeding events in patients with venous thromboembolism on stable anticoagulation treatment.

2016

Attempts at identifying patients with an elevated risk of bleeding while on anticoagulation following acute venous thromboembolism (VTE) have largely been unsuccessful thus far. We sought to develop a clinical prediction score for bleeding during stable anticoagulation treatment after acute VTE.We performed a post hoc analysis of the pooled RE-COVER studies, two double-blind randomised “sister” trials evaluating dabigatran versus standard treatment in 5107 VTE patients.A score was derived from patients randomised to dabigatran using logistic regression analysis covering the complete follow-up period. The final model, named VTE-BLEED, included six variables and yielded a c-statistic of 0.72 …

Pulmonary and Respiratory MedicineAdultMalemedicine.medical_specialtyAdolescentPopulationDecision MakingHemorrhage030204 cardiovascular system & hematologySensitivity and SpecificitySeverity of Illness Indexlaw.inventionDabigatranCohort Studies03 medical and health sciencesYoung Adult0302 clinical medicineRandomized controlled triallawRisk FactorsSeverity of illnessPost-hoc analysisMedicineHumans030212 general & internal medicineeducationAgedAged 80 and overeducation.field_of_studyModels Statisticalbusiness.industryStandard treatmentWarfarinAnticoagulantsVenous ThromboembolismSurgeryDabigatranROC CurveData Interpretation StatisticalRegression AnalysisFemaleWarfarinbusinessAlgorithmsCohort studymedicine.drugThe European respiratory journal
researchProduct

Efficacy of C1 esterase inhibitor concentrate in treatment of cutaneous attacks of hereditary angioedema.

2015

BACKGROUND Although treatment with C1 esterase inhibitor (C1-INH) concentrate is well established for hereditary angioedema (HAE) attacks in general, data that assess its efficacy for cutaneous attack treatment are sparse. OBJECTIVE To assess efficacy of plasma-derived, nanofiltered C1-INH concentrate for cutaneous attack treatment by comparing treated attacks from the uncontrolled I.M.P.A.C.T.2 study with historical data for untreated attacks. METHODS Cutaneous attack data from patients with HAE who were treated for cutaneous edema with 20 IU/kg body weight C1-INH concentrate in the uncontrolled I.M.P.A.C.T.2 study (38 patients) were compared with data from untreated patients from an histo…

Pulmonary and Respiratory MedicineAdultMalemedicine.medical_specialtyAdolescentUntreated groupPeripheral edemaGastroenterologySeverity of Illness IndexYoung AdultInternal medicineSeverity of illnessmedicineImmunology and AllergyHumansYoung adultChildAgedEnd pointbusiness.industryAngioedemas HereditaryGeneral MedicineArticlesMiddle Agedmedicine.diseasePeripheralC1 esteraseTreatment OutcomeHereditary angioedemaDisease ProgressionFemalemedicine.symptombusinessComplement C1 Inhibitor ProteinAllergy and asthma proceedings
researchProduct

Omalizumab provides long-term control in patients with moderate-to-severe allergic asthma.

2002

The ability of omalizumab, an anti-immnoglobulin-E agent, to maintain long-term disease control in patients with moderate-to-severe allergic asthma was investigated in a 24-week double-blind extension to a 28-week core trial. During the extension, 483 of the initial 546 patients were maintained on randomised treatment and the lowest sustainable dose of beclomethasone dipropionate (BDP) as established during the steroid-reduction phase of the core trial. The use of concomitant asthma medication was permitted and investigators were allowed to adjust the BDP dose or switch patients from BDP to other asthma medications if deemed necessary. More omalizumab-treated patients (33.5%) than placebo-t…

Pulmonary and Respiratory MedicineAdultMalemedicine.medical_specialtyAllergyTime FactorsAdolescentOmalizumabOmalizumabImmunoglobulin EPlaceboAntibodies Monoclonal HumanizedSeverity of Illness Indexlaw.inventionRandomized controlled trialDouble-Blind MethodlawInternal medicinemedicineHypersensitivityHumansAnti-Asthmatic AgentsAdverse effectChildAsthmaAgedbiologyDose-Response Relationship Drugbusiness.industryBeclomethasoneAntibodies MonoclonalMiddle Agedmedicine.diseaseAsthmaSurgeryAntibodies Anti-IdiotypicTreatment OutcomeConcomitantbiology.proteinFemalebusinessmedicine.drugFollow-Up StudiesThe European respiratory journal
researchProduct

Asthma management in a specialist setting: Results of an Italian Respiratory Society survey.

2017

Abstract Background Asthma considerably impairs patients' quality of life and increases healthcare costs. Severity, morbidity, and degree of disease control are the major drivers of its clinical and economic impact. National scientific societies are required to monitor the application of international guidelines and to adopt strategies to improve disease control and better allocate resources. Aim to provide a detailed picture of the characteristics of asthma patients and modalities of asthma management by specialists in Italy and to develop recommendations for the daily management of asthma in a specialist setting. Method: A quantitative research program was implemented. Data were collected…

Pulmonary and Respiratory MedicineAdultMalemedicine.medical_specialtyConcordanceSocio-culturalePractice PatternsSettore MED/10 - Malattie Dell'Apparato RespiratorioSeverity of Illness Index03 medical and health sciences0302 clinical medicineQuality of life (healthcare)Retrospective StudieSurveys and QuestionnairesSeverity of illnessHealth caremedicineSurveys and QuestionnaireHumansPharmacology (medical)030212 general & internal medicinePractice Patterns Physicians'Adult; Aged; Asthma; Female; Humans; Italy; Male; Middle Aged; Practice Patterns Physicians'; Retrospective Studies; Severity of Illness Index; Surveys and Questionnaires; Quality of Life; SpecializationAsthmaAgedRetrospective StudiesModalitiesPhysicians'business.industryBiochemistry (medical)Retrospective cohort studyMiddle Agedmedicine.diseaseAsthmaPulmonary and Respiratory Medicine; Biochemistry (medical); Pharmacology (medical)030228 respiratory systemItalyTest scoreFamily medicinePhysical therapyQuality of LifeFemalebusinessHumanSpecializationPulmonary pharmacologytherapeutics
researchProduct

Metabolic syndrome, insulin resistance and sleepiness in real-life obstructive sleep apnoea.

2011

The metabolic syndrome shows a variable prevalence in obstructive sleep apnoea (OSA), and its association with insulin resistance or excessive daytime sleepiness in OSA is unclear. This study assessed the following in consecutive patients with newly diagnosed OSA: 1) the prevalence of metabolic syndrome; and 2) its association with insulin resistance and daytime sleepiness. Metabolic syndrome (National Cholesterol Education Program Adult Treatment Panel (NCEP- ATP) III criteria), insulin resistance (Homeostatic Model Assessment (HOMA) index, n5288) and daytime sleepiness (Epworth Sleepiness Scale) were assessed in 529 OSA patients. The prevalence of metabolic syndrome was 51.2%, which incre…

Pulmonary and Respiratory MedicineAdultMalemedicine.medical_specialtyExcessive daytime sleepinessBlood PressureSettore MED/10 - Malattie Dell'Apparato RespiratorioSeverity of Illness IndexBody Mass IndexInsulin resistanceSex FactorsInternal medicinemedicinePrevalenceHumansObesityAgedMetabolic SyndromeSleep Apnea Obstructivebusiness.industryEpworth Sleepiness ScaleSleep apneaMiddle Agedmedicine.diseaseObesityrespiratory tract diseasesOxygenEndocrinologyEpidemiology intermittent hypoxia metabolism sexHomeostatic model assessmentCardiologyFemaleSleep StagesMetabolic syndromemedicine.symptomInsulin ResistancebusinessBody mass indexBiomarkersThe European respiratory journal
researchProduct